How Aphria (TSX:APHA) Stock Is Placed After Strong Q3

Aphria (TSX:APHA)(NYSE:APHA) stock soared more than 20% this week after reporting strong Q3 earnings. Is it readying to break the roof?

Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Aphria (TSX:APHA)(NYSE:APHA), the top pot stock of Canada, has surged more than 20% so far this week. The rally is evident given yet another strong quarterly earnings yesterday. There are several encouraging signs for investors beyond its Q3 earnings, which indicates that this rally could be just the beginning.

Aphria reports yet another strong quarter

A $1.4 billion Aphria reported revenues of $144 million for the quarter ended February 29. This represented a growth of 96% year over year. Notably, this was Aphria’s ninth consecutive quarter of close to 100% or higher revenue growth.

To put that in perspective, it reported total revenues of $20 million in the fiscal year 2017, increasing to $520 million in the last 12 months. The company could continue to exhibit such rapid growth in the next few years given its aggressive international expansion plans and new product launches. Aphria reported earnings of $5.7 million in the recently reported quarter.

The lockdowns are expected to significantly reduce the footfall in physical stores, which will hamper the top lines of cannabis players. However, the government of Ontario, the most populous province in Canada, recently allowed cannabis stores to operate temporarily for pickup and deliveries.

This will likely minimize the dent on top lines of these cannabis companies such as Aphria. However, the pandemic-driven uncertainties have made Aphria’s management to rescind guidance for the full year.

Aphria stands tall among peers

Many players in the cannabis industry are struggling on several fronts. Many loss-making companies are tussling to raise new capital to keep things going. However, Aphria is not only profitable; it is well capitalized as well. As per its recent release, it had cash and equivalents of $515 million, which will probably be enough to traverse these harsh times.

Aphria notably differentiates itself from peers with its extensive distribution network in entire Canada. It has an annual production capacity of 255,000 kilograms, making it one of the biggest cannabis players. It estimates a US$200 billion cannabis market worldwide with significant growth opportunities in adult-use cannabis and derivatives.

Valuation

Just like other cannabis stocks, Aphria was also weak, particularly since last year. It is currently trading 50% lower to its 52-week high of $10.8. However, it looks attractive from the valuation standpoint.

It is trading 2.5 times its next year’s expected revenues. This might appear stretched on an absolute basis, but growth stocks trade at a premium. Also, Aphria deserves this premium, as it stands tall among peers on many parametres.

In comparison, peer Canopy Growth is trading at a much larger premium at the moment. It has lost approximately 30% so far this year. Aurora Cannabis stock also looks to be trading at a large premium at the moment. It has lost more than 60% so far this year.

Aphria stock could continue to trade notably volatile like many of its peers in the near future. However, it mainly stands tall compared to peers because of its strong cash position and convincing financials. It is indeed an attractive investment proposition for long-term investors in the risky cannabis industry.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vineet Kulkarni has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »